文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

高危再插管患者亚组中预防性无创通气的获益:一项事后分析

Benefit with preventive noninvasive ventilation in subgroups of patients at high-risk for reintubation: a post hoc analysis.
PubMed 文献 · J Intensive Care · 2022-09-11
一句话结论再插管高危因素≥4个的患者预防性NIV可能获益更多,超重患者预防性HFNC再插管风险更高,作者认为HFNC可能不是超重患者的最佳预防治疗。

本文为一项多中心、随机、对照、非劣效性试验的未预先设定的事后分析,比较经鼻高流量氧疗(HFNC)与无创通气(NIV)预防再插管。原研究纳入604例至少1个再插管危险因素的患者,其中148例BMI≥25 kg/m2。校正协变量后,≥4个危险因素患者(208例)再插管风险更高(OR 3.4 [95%CI 2.16-5.35]);该组接受预防性NIV者再插管率更低(23.9% vs 45.7%;P=0.001)。超重患者校正后再插管风险未显著升高(OR 1.37 [95%CI 0.82-2.29]),但接受预防性HFNC时再插管风险升高(OR 2.47 [95%CI 1.18-5.15])。作者认为≥4个危险因素患者可能更多获益于预防性NIV,HFNC可能不是超重患者的最佳预防治疗,需专门试验证实。

要点

  • 校正协变量后,≥4个再插管危险因素患者(208例)再插管风险更高(OR 3.4 [95%CI 2.16-5.35])。
  • ≥4个危险因素患者接受预防性NIV者再插管率低于对照(23.9% vs 45.7%;P=0.001)。
  • 超重(BMI≥25 kg/m2)患者校正后再插管风险未显著升高(OR 1.37 [95%CI 0.82-2.29])。
  • 超重患者接受预防性HFNC时再插管风险升高(OR 2.47 [95%CI 1.18-5.15])。
  • 作者认为≥4个危险因素患者可能更多获益于预防性NIV,HFNC可能不是超重患者的最佳预防治疗。

适用人群与场景

  • 原研究纳入至少1个再插管危险因素的患者,共604例;本事后分析中BMI≥25 kg/m2者148例,≥4个危险因素者208例。

研究设计与关键结果

  • 研究类型:多中心、随机、对照、非劣效性试验的未预先设定事后分析,比较HFNC与NIV预防再插管。
  • 原研究纳入604例至少1个再插管危险因素的患者,其中148例BMI≥25 kg/m2。
  • 校正潜在协变量后,≥4个危险因素患者(208例)再插管风险更高(OR 3.4 [95%CI 2.16-5.35])。
  • ≥4个危险因素患者接受预防性NIV者再插管率低于对照(23.9% vs 45.7%;P=0.001)。
  • 超重患者校正协变量后再插管风险未显著升高(OR 1.37 [95%CI 0.82-2.29])。
  • 超重患者接受预防性HFNC时再插管风险升高(OR 2.47 [95%CI 1.18-5.15])。

证据类型、等级与局限

  • 证据类型:多中心、随机、对照、非劣效性试验的未预先设定事后分析。
  • 局限:原文为事后分析且未预先设定;作者指出需专门试验证实这些结果。

对床旁实践的改变

  • 作者认为,≥4个再插管危险因素的患者可能更多获益于预防性NIV。
  • 作者认为,基于该结果,HFNC可能不是超重患者的最佳预防治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: High-flow nasal cannula (HFNC) was shown to be non-inferior to noninvasive ventilation (NIV) for preventing reintubation in a general population of high-risk patients. However, some subgroups of high-risk patients might benefit more from NIV. We aimed to determine whether the presence of many risk factors or overweight (body mass index (BMI) ≥ 25 kg/m2) patients could have different response to any preventive therapy, NIV or HFNC in terms of reduced reintubation rate.

METHODS: Not pre-specified post hoc analysis of a multicentre, randomized, controlled, non-inferiority trial comparing NFNC and NIV to prevent reintubation in patients at risk for reintubation. The original study included patients with at least 1 risk factor for reintubation.

RESULTS: Among 604 included in the original study, 148 had a BMI ≥ 25 kg/m2. When adjusting for potential covariates, patients with ≥ 4 risk factors (208 patients) presented a higher risk for reintubation (OR 3.4 [95%CI 2.16-5.35]). Patients with ≥ 4 risk factors presented lower reintubation rates when treated with preventive NIV (23.9% vs 45.7%; P = 0.001). The multivariate analysis of overweight patients, adjusted for covariates, did not present a higher risk for reintubation (OR 1.37 [95%CI 0.82-2.29]). However, those overweight patients presented an increased risk for reintubation when treated with preventive HFNC (OR 2.47 [95%CI 1.18-5.15]).

CONCLUSIONS: Patients with ≥ 4 risk factors for reintubation may benefit more from preventive NIV. Based on this result, HFNC may not be the optimal preventive therapy in overweight patients. Specific trials are needed to confirm these results.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Hernández G, Vaquero C, Ortiz R, et al. Benefit with preventive noninvasive ventilation in subgroups of patients at high-risk for reintubation: a post hoc analysis. J Intensive Care. 2022. PMID: 36089625. doi:10.1186/s40560-022-00635-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。